Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Proteoderm, a wholly owned subsidiary of Proteonomix, a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, has developed a new formulation. It is expected to be available only at licensed health professionals' offices.
Subscribe to our email newsletter
Proteoderm said that the new product, Proteoderm PS (physician strength) is designed to provide a specific dosage of the active ingredient Matrix NC-138, to the patient depending on the patient’s skin type and genomic analysis. Proteoderm PS is expected to provide the optimal strength of the active ingredient for each user.
Proteoderm stated that the physician strength Proteoderm PS is expected to be available only through a physician and health care network. The company anticipates that Proteoderm is expected to expand its product line.
Michael Cohen, CEO of Proteonomix, said: “Our research and development continues to take our laboratory efforts and apply them to commercialisation.
“We expect Proteoderm to add additional revenues to our sales of Proteoderm PS, and have a contribution to the company’s product line.”